An exploratory, randomised, double-blind, placebo controlled, 14 day, two-way crossover, Inhaled Allergen Challenge (IAC) study to evaluate the effects of SMP-028 in subjects with mild to moderate asthma.

Trial Profile

An exploratory, randomised, double-blind, placebo controlled, 14 day, two-way crossover, Inhaled Allergen Challenge (IAC) study to evaluate the effects of SMP-028 in subjects with mild to moderate asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2012

At a glance

  • Drugs SMP 028 (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms IAC-SMP028
  • Sponsors Dainippon Sumitomo Pharma
  • Most Recent Events

    • 01 Apr 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 17 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top